P. N. Jeal

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

Viviana Galimberti, Bernard F. Cole, Giuseppe Viale, Paolo Veronesi et autres

it, us, si, au, ch (code pays fourni par la source)

Cytotoxic chemotherapy and radiotherapy in a patient with breast cancer and variegate porphyria (VP)

John D. Scarlett, June Corry, P. N. Jeal

au (code pays fourni par la source)

A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer.

Danny Rischin, Bishop J, Olver In, Laidlaw Cr et autres

Sixty-seven patients with advanced breast cancer were prospectively entered into a Phase II trial of cyclophosphamide 100 mg/m2 orally on days 1-14, methotrexate 40 mg/m2 intravenously (i.v.) on day 1, 5-fluorouracil 600 mg/m2 i.v. on day 1, and prednisolone 40 mg/m2 orally …

au (code pays fourni par la source)

Symptomatic choroidal metastases in breast cancer

Rowan G. Doig, Ian Olver, P. N. Jeal, James F. Bishop

A series of 21 consecutive patients with carcinoma of the breast and symptomatic choroidal metastases was reviewed. All patients were symptomatic of choroidal metastases at presentation. Most patients had disease progression at other sites at the time of diagnosis. The incidence of …

au (code pays fourni par la source)

Evaluation of an inhibition enzyme immunoassay kit for mammary serum antigen (MSA)

Guy T. Layton, J Golder, S. Claiborne Johnston, Michael A. McGuckin et autres

The measurement of Mammary Serum Antigen (MSA) levels by a research inhibition enzyme immunoassay (EIA) using the monoclonal antibody (Mab) 3E1.2 has previously been shown to be a highly-sensitive marker in breast cancer, particularly in stage I/II of the disease process. We …

Dose-intense weekly cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFP) in advanced breast cancer

Jonathan Cebon, JF Bishop, V. Harvey, Bridgett Mason et autres

au, nz (code pays fourni par la source)

Improving the Quality of Life during Chemotherapy for Advanced Breast Cancer

Alan S. Coates, Val Gebski, James F. Bishop, P. N. Jeal et autres

Since chemotherapy for metastatic breast cancer is not curative, consideration of the quality of life is important in selecting a treatment regimen. We conducted a randomized trial comparing continuous chemotherapy, administered until disease progression was evident, with intermittent therapy, whereby treatment was …

au (code pays fourni par la source)

Mitomycin and mitoxantrone in previously treated patients with advanced breast cancer.

James F. Bishop, Derek Raghavan, Ryan Woods, Anne C. Coates et autres

A total of 56 heavily pretreated patients with advanced breast cancer were treated with the combination mitomycin and mitoxantrone. Partial responses were seen in ten of 56 patients (18%), or ten of 44 (23%) completing two courses, while 18 (32%) had stable …